Affordable Access

Download Read

Discovery and Characterization of R/S-N-3-Cyanophenyl-N'- (6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H- 1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity Against Cancer Cell Lines. ACS Paragon Plus Environment Journal of Medicinal Chemistry

Authors
Type
Published Article
Journal
Journal of Medicinal Chemistry
0022-2623
Publisher
American Chemical Society
Publication Date
Identifiers
DOI: 10.1021/acs.jmedchem.7b00533
Source
LBMCC

Abstract

A new series of N-aryl-N'-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)ureas bearing an alkoxycarbonylamino group at the 6-position were synthesized and examined as putative anticancer agents targeting sirtuins in glioma cells. Based on computational docking combined to in vitro sirtuin 1/2 inhibition assays, we selected compound 18 [R/S-N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea] which displays a potent antiproliferative activity on various glioma cell types, assessed by quantitative videomicroscopy, eventually triggering senescence. The impact on normal glial cells was lower with a selectivity index > 10. Furthermore, human U373 and Hs683 glioblastoma cell lines served to demonstrate the inhibitory activity of 18 against histone deacetylase (HDAC) class III sirtuins 1 and 2 (SIRT1/2) by quantifying acetylation levels of histone and non-histone proteins. The translational potential of 18 was validated by an NCI-60 cell line screen and validation of growth inhibition of drug resistant cancer cell models. Eventually, the anticancer potential of 18 was validated in 3D glioblastoma spheroids and in vivo by zebrafish xenografts. In summary, compound 18 is the first representative of a new class of SIRT inhibitors opening new perspectives in the medicinal chemistry of HDAC inhibitors

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen 128 times
Downloaded <100 times
0 Comments